Cannabidiol decreases bone resorption by inhibiting RANK/RANKL expression and pro-inflammatory cytokines during experimental periodontitis in rats.
Cannabidiol (CBD) is a cannabinoid component from Cannabis sativa that does not induce psychotomimetic effects and possess anti-inflammatory properties. In the present study we tested the effects of CBD in a periodontitis experimental model in rats. We also investigated possible mechanisms underlying these effects. Periodontal disease was induced by a ligature placed around the mandible first molars of each animal. Male Wistar rats were divided into 3 groups: control animals; ligature-induced animals treated with vehicle and ligature-induced animals treated with CBD (5 mg/kg, daily). Thirty days after the induction of periodontal disease the animals were sacrificed and mandibles and gingival tissues removed for further analysis. Morphometrical analysis of alveolar bone loss demonstrated that CBD-treated animals presented a decreased alveolar bone loss and a lower expression of the activator of nuclear factor-kappaB ligand RANKL/RANK. Moreover, gingival tissues from the CBD-treated group showed decreased neutrophil migration (MPO assay) associated with lower interleukin (IL)-1beta and tumor necrosis factor (TNF)-alpha production. These results indicate that CBD may be useful to control bone resorption during progression of experimental periodontitis in rats.
Napimoga
Marcelo H
MH
Laboratory of Molecular Biology, University of Uberaba, Brazil. marcelo.napimoga@uniube.br
Benatti
Bruno B
BB
Lima
Flavia O
FO
Alves
Polyanna M
PM
Campos
Alline C
AC
Pena-Dos-Santos
Diego R
DR
Severino
Fernando P
FP
Cunha
Fernando Q
FQ
Guimarães
Francisco S
FS
D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use*; D001862:Bone Resorption / Q000188:drug therapy* / Q000209:etiology / Q000473:pathology; D002185:Cannabidiol / Q000627:therapeutic use*; D002465:Cell Movement / Q000187:drug effects / Q000276:immunology; D016207:Cytokines / Q000037:antagonists & inhibitors*; D004195:Disease Models, Animal; D008297:Male; D009504:Neutrophils / Q000187:drug effects / Q000276:immunology / Q000378:metabolism; D010518:Periodontitis / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D009195:Peroxidase / Q000276:immunology / Q000378:metabolism; D053245:RANK Ligand / Q000037:antagonists & inhibitors*; D051381:Rats; D017208:Rats, Wistar; D053246:Receptor Activator of Nuclear Factor-kappa B / Q000037:antagonists & inhibitors*
D000894:Anti-Inflammatory Agents, Non-Steroidal; D016207:Cytokines; D053245:RANK Ligand; D053246:Receptor Activator of Nuclear Factor-kappa B; D002185:Cannabidiol; D009195:Peroxidase